logo

For the Inventor, By the Inventor

Wallingford, CT, United States of America

Valentin K Gribkoff

This inventor holds 17 USPTO granted patents and 10 published patent applications, primarily in Potassium Channel Modulation. Top assignees: Bristol-Myers Squibb Compnay, Knopp Neurosciences, Inc., Bristol-Myers Squibb. Active years: 1996-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Valentin K Gribkoff. Retrieved from https://idiyas.com/inventor/valentin-k-gribkoff

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 

% Patents Active = 94.1

Average Co-Inventor Count = 3.6

ph-index = 10

Forward Citations = 223(Granted Patents)


Company Filing History:

goldMedal10 out of 3,745 
 
Bristol-Myers Squibb Compnay
 patents
silverMedal4 out of 5 
 
Knopp Neurosciences, Inc.
 patents
bronzeMedal1 out of 39 
 
Bristol-Myers Squibb
 patents
4. 1 out of 27 
 
Knopp Biosciences, LLC
 patents
5. 1 out of 834,570 
Other
 patents

Years Active: 1996-2017

Loading Chart...
Areas of Expertise:
Potassium Channels
Pramipexole
Formulations
Modulators
Oxindole Derivatives
KCNQ Channels
Atropisomers
Melatonin Receptor
Transmembrane Conductance
Imidazoles
Triazoles
Oxadiazolones
17 patents (USPTO):Explore Patents
1. 9849116 - Compositions and methods of using (R)-pramipexole (2017-12-26),
2. 8524695 - Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same (2013-09-03),
3. 8518926 - Compositions and methods of using (R)-pramipexole (2013-08-27),
4. 8445474 - Compositions of R(+) and S(−) pramipexole and methods of using the same (2013-05-21),
5. 8017598 - Compositions of R(+) and S(−) pramipexole and methods of using the same (2011-09-13),
6. 7041496 - DNA encoding rodent KCNQ2 potassium channel (2006-05-09),
7. 6939968 - Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives (2005-09-06),
8. 6893858 - Human kcnq5 potassium channel, methods and compositions thereof (2005-05-17),
9. 6855829 - 3-fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related disease (2005-02-15),
10. 6469042 - Fluoro oxindole derivatives as modulators if KCNQ potassium channels (2002-10-22),
11. 6326526 - Melatonin receptor-deficient mice and uses thereof (2001-12-04),
12. 6271249 - Diphenyl imidazoles as potassium channel modulators (2001-08-07),
13. 6077861 - Diphenyl triazoles as potassium channel modulators (2000-06-20),
14. 5869509 - Diphenyl oxadiazolones as potassium channel modulators (1999-02-09),
15. 5621007 - Method for regulation of transmembrane chloride conductance (1997-04-15),

Title: The Innovative Contributions of Valentin K Gribkoff

Introduction

Valentin K Gribkoff is a notable inventor based in Wallingford, CT, with a remarkable portfolio of 17 patents. His work primarily focuses on pharmaceutical compositions and methods that address various neurodegenerative diseases and related conditions.

Latest Patents

Gribkoff's latest patents include compositions and methods of using (R)-pramipexole, which involve pharmaceutical compositions that combine (R)-pramipexole with secondary therapeutic agents. These agents may include dopamine agonists, COMT inhibitors, and neurotrophic factors, among others. Another significant patent involves modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine, aimed at treating neurodegenerative diseases through controlled release mechanisms.

Career Highlights

Throughout his career, Gribkoff has made significant contributions while working with prominent companies such as Bristol-Myers Squibb Company and Knopp Neurosciences, Inc. His expertise in pharmaceutical development has led to advancements in treatments for conditions related to mitochondrial dysfunction and oxidative stress.

Collaborations

Gribkoff has collaborated with esteemed colleagues, including Piyasena Hewawasam and Nicholas A Meanwell, to further enhance the impact of his research and innovations in the pharmaceutical field.

Conclusion

Valentin K Gribkoff's innovative work in the pharmaceutical industry has led to significant advancements in the treatment of neurodegenerative diseases. His contributions continue to influence the development of effective therapeutic solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…